| Inbound Relationships |
Type |
Active |
Source |
Characteristic |
Refinability |
Group |
| Product containing precisely paracetamol 80 milligram/1 each conventional release oral capsule (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Non-opioid analgesic (substance) |
Inferred relationship |
Some |
|
| Product containing precisely paracetamol 160 milligram/1 each conventional release oral capsule (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Non-opioid analgesic (substance) |
Inferred relationship |
Some |
|
| Acetaminophen 80mg/0.8mL drops |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Non-opioid analgesic (substance) |
Inferred relationship |
Some |
|
| Acetaminophen 80mg/2.5mL elixir |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Non-opioid analgesic (substance) |
Inferred relationship |
Some |
|
| Acetaminophen 80mg/5mL elixir |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Non-opioid analgesic (substance) |
Inferred relationship |
Some |
|
| Acetaminophen 160mg/5mL elixir |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Non-opioid analgesic (substance) |
Inferred relationship |
Some |
|
| Acetaminophen 500mg/15mL oral liquid |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Non-opioid analgesic (substance) |
Inferred relationship |
Some |
|
| Product containing precisely paracetamol 48.2 milligram/1 milliliter conventional release oral solution (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Non-opioid analgesic (substance) |
Inferred relationship |
Some |
|
| Acetaminophen + chloralantipyrine + isometheptene mucate (1:1) 325mg/100mg/65mg capsule |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Non-opioid analgesic (substance) |
Inferred relationship |
Some |
|
| Acetaminophen + chlorpheniramine maleate + phenylephrine hydrochloride 500mg/8mg/40mg caplets |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Non-opioid analgesic (substance) |
Inferred relationship |
Some |
|
| Acetaminophen + alcohol + codeine phosphate 120mg/7%vv/12mg elixir |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Non-opioid analgesic (substance) |
Inferred relationship |
Some |
|
| Acetaminophen + codeine phosphate 120mg/12mg suspension |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Non-opioid analgesic (substance) |
Inferred relationship |
Some |
|
| Product containing precisely codeine phosphate 15 milligram and paracetamol 300 milligram/1 each conventional release oral tablet (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Non-opioid analgesic (substance) |
Inferred relationship |
Some |
|
| Codeine phosphate 30 mg and paracetamol 300 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Non-opioid analgesic (substance) |
Inferred relationship |
Some |
|
| Product containing precisely codeine phosphate 60 milligram and paracetamol 300 milligram/1 each conventional release oral tablet (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Non-opioid analgesic (substance) |
Inferred relationship |
Some |
|
| Acetaminophen + dichloralantipyrine + isometheptene mucate (1:1) 325mg/100mg/65mg capsule |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Non-opioid analgesic (substance) |
Inferred relationship |
Some |
|
| Product containing precisely hydrocodone bitartrate 10 milligram and paracetamol 325 milligram/1 each conventional release oral tablet (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Non-opioid analgesic (substance) |
Inferred relationship |
Some |
|
| Hydrocodone bitartrate 5 mg and paracetamol 325 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Non-opioid analgesic (substance) |
Inferred relationship |
Some |
|
| Hydrocodone bitartrate 10 mg and paracetamol 500 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Non-opioid analgesic (substance) |
Inferred relationship |
Some |
|
| Hydrocodone bitartrate 5 mg and paracetamol 500 mg oral capsule |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Non-opioid analgesic (substance) |
Inferred relationship |
Some |
|
| Product containing precisely hydrocodone bitartrate 5 milligram and paracetamol 500 milligram/1 each conventional release oral tablet (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Non-opioid analgesic (substance) |
Inferred relationship |
Some |
|
| Acetaminophen + hydrocodone bitartrate 500mg/7.5mg elixir |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Non-opioid analgesic (substance) |
Inferred relationship |
Some |
|
| Hydrocodone bitartrate 7.5 mg and paracetamol 500 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Non-opioid analgesic (substance) |
Inferred relationship |
Some |
|
| Hydrocodone bitartrate 5 mg and paracetamol 556 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Non-opioid analgesic (substance) |
Inferred relationship |
Some |
|
| Product containing precisely hydrocodone bitartrate 10 milligram and paracetamol 650 milligram/1 each conventional release oral tablet (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Non-opioid analgesic (substance) |
Inferred relationship |
Some |
|
| Product containing precisely hydrocodone bitartrate 7.5 milligram and paracetamol 650 milligram/1 each conventional release oral tablet (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Non-opioid analgesic (substance) |
Inferred relationship |
Some |
|
| Hydrocodone bitartrate 10 mg and paracetamol 660 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Non-opioid analgesic (substance) |
Inferred relationship |
Some |
|
| Product containing precisely hydrocodone bitartrate 7.5 milligram and paracetamol 750 milligram/1 each conventional release oral tablet (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Non-opioid analgesic (substance) |
Inferred relationship |
Some |
|
| Acetaminophen + orphenadrine citrate 500mg/50mg caplets |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Non-opioid analgesic (substance) |
Inferred relationship |
Some |
|
| Acetaminophen + oxycodone hydrochloride 325mg/5mg solution |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Non-opioid analgesic (substance) |
Inferred relationship |
Some |
|
| Product containing precisely oxycodone hydrochloride 5 milligram and paracetamol 325 milligram/1 each conventional release oral tablet (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Non-opioid analgesic (substance) |
Inferred relationship |
Some |
|
| Acetaminophen + oxycodone hydrochloride 500mg/5mg caplets |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Non-opioid analgesic (substance) |
Inferred relationship |
Some |
|
| Product containing precisely oxycodone hydrochloride 5 milligram and paracetamol 500 milligram/1 each conventional release oral capsule (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Non-opioid analgesic (substance) |
Inferred relationship |
Some |
|
| Paracetamol 650mg / pentazocine hydrochloride 25mg caplet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Non-opioid analgesic (substance) |
Inferred relationship |
Some |
|
| Product containing precisely paracetamol 300 milligram and phenyltoloxamine citrate 20 milligram and salicylamide 200 milligram/1 each conventional release oral capsule (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Non-opioid analgesic (substance) |
Inferred relationship |
Some |
|
| Paracetamol 300 mg and phenyltoloxamine citrate 20 mg and salicylamide 200 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Non-opioid analgesic (substance) |
Inferred relationship |
Some |
|
| Dextropropoxyphene napsylate 50 mg and paracetamol 325 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Non-opioid analgesic (substance) |
Inferred relationship |
Some |
|
| Dextropropoxyphene napsylate 100 mg and paracetamol 650 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Non-opioid analgesic (substance) |
Inferred relationship |
Some |
|
| Paracetamol 250 mg and salicylamide 600 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Non-opioid analgesic (substance) |
Inferred relationship |
Some |
|
| Acetaminophen 125mg suppository |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Non-opioid analgesic (substance) |
Inferred relationship |
Some |
|
| Product containing hydrocodone bitartrate and paracetamol |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Non-opioid analgesic (substance) |
Inferred relationship |
Some |
|
| Tramadol (substance) |
Is a |
False |
Non-opioid analgesic (substance) |
Inferred relationship |
Some |
|
| Dihydroergotamine (substance) |
Is a |
False |
Non-opioid analgesic (substance) |
Inferred relationship |
Some |
|
| Acetaminophen 120mg suppository |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Non-opioid analgesic (substance) |
Inferred relationship |
Some |
|
| Acetaminophen 160mg/5mL liquid |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Non-opioid analgesic (substance) |
Inferred relationship |
Some |
|
| Acetaminophen 500mg tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Non-opioid analgesic (substance) |
Inferred relationship |
Some |
|
| Product containing precisely hydrocodone bitartrate 10 milligram and paracetamol 400 milligram/1 each conventional release oral tablet (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Non-opioid analgesic (substance) |
Inferred relationship |
Some |
|
| Acetaminophen 250mg oro-dispersible tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Non-opioid analgesic (substance) |
Inferred relationship |
Some |
|
| Paracetamol 1g/sachet powder |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Non-opioid analgesic (substance) |
Inferred relationship |
Some |
|
| Poisoning caused by paracetamol |
Causative agent (attribute) |
False |
Non-opioid analgesic (substance) |
Inferred relationship |
Some |
|
| Product containing levomepromazine (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Non-opioid analgesic (substance) |
Inferred relationship |
Some |
|
| Product containing paracetamol (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Non-opioid analgesic (substance) |
Inferred relationship |
Some |
|
| Product containing precisely butalbital 50 milligram and paracetamol 325 milligram/1 each conventional release oral capsule (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Non-opioid analgesic (substance) |
Inferred relationship |
Some |
|
| Butalbital 50 mg and caffeine 40 mg and codeine phosphate 30 mg and paracetamol 325 mg oral capsule |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Non-opioid analgesic (substance) |
Inferred relationship |
Some |
|
| Product containing precisely butalbital 50 milligram and caffeine 40 milligram and paracetamol 325 milligram/1 each conventional release oral capsule (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Non-opioid analgesic (substance) |
Inferred relationship |
Some |
|
| Product containing precisely butalbital 50 milligram and caffeine 40 milligram and paracetamol 325 milligram/1 each conventional release oral tablet (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Non-opioid analgesic (substance) |
Inferred relationship |
Some |
|
| Product containing precisely butalbital 50 milligram and caffeine 40 milligram and paracetamol 500 milligram/1 each conventional release oral capsule (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Non-opioid analgesic (substance) |
Inferred relationship |
Some |
|
| Product containing precisely butalbital 50 milligram and caffeine 40 milligram and paracetamol 500 milligram/1 each conventional release oral tablet (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Non-opioid analgesic (substance) |
Inferred relationship |
Some |
|
| Butalbital 50 mg and paracetamol 325 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Non-opioid analgesic (substance) |
Inferred relationship |
Some |
|
| Product containing precisely butalbital 50 milligram and paracetamol 650 milligram/1 each conventional release oral capsule (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Non-opioid analgesic (substance) |
Inferred relationship |
Some |
|
| Butalbital 50 mg and paracetamol 650 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Non-opioid analgesic (substance) |
Inferred relationship |
Some |
|
| Caffeine 30 mg and dihydrocodeine tartrate 16 mg and paracetamol 356.4 mg oral capsule |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Non-opioid analgesic (substance) |
Inferred relationship |
Some |
|
| Product containing precisely caffeine 100 milligram and isometheptene mucate 65 milligram and paracetamol 325 milligram/1 each conventional release oral capsule (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Non-opioid analgesic (substance) |
Inferred relationship |
Some |
|
| Product containing precisely dichloralphenazone 100 milligram and isometheptene 65 milligram and paracetamol 325 milligram/1 each conventional release oral capsule (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Non-opioid analgesic (substance) |
Inferred relationship |
Some |
|
| Acetaminophen + phenyltoloxamine citrate 500mg/30mg caplets |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Non-opioid analgesic (substance) |
Inferred relationship |
Some |
|
| Paracetamol 500 mg and phenyltoloxamine citrate 50 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Non-opioid analgesic (substance) |
Inferred relationship |
Some |
|
| Paracetamol 500 mg and phenyltoloxamine citrate 60 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Non-opioid analgesic (substance) |
Inferred relationship |
Some |
|
| Paracetamol 650 mg and phenyltoloxamine citrate 50 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Non-opioid analgesic (substance) |
Inferred relationship |
Some |
|
| Acetaminophen 650mg/25mL liquid |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Non-opioid analgesic (substance) |
Inferred relationship |
Some |
|
| Acetaminophen + pentazocine hydrochloride |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Non-opioid analgesic (substance) |
Inferred relationship |
Some |
|
| Product containing dichloralphenazone and isometheptene and paracetamol (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Non-opioid analgesic (substance) |
Inferred relationship |
Some |
|
| Product containing precisely hydrocodone bitartrate 2.5 milligram and paracetamol 500 milligram/1 each conventional release oral tablet (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Non-opioid analgesic (substance) |
Inferred relationship |
Some |
|
| Product containing caffeine and isometheptene mucate and paracetamol |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Non-opioid analgesic (substance) |
Inferred relationship |
Some |
|
| Product containing paracetamol and phenyltoloxamine citrate |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Non-opioid analgesic (substance) |
Inferred relationship |
Some |
|
| Acetaminophen + alcohol + codeine phosphate |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Non-opioid analgesic (substance) |
Inferred relationship |
Some |
|
| Acetaminophen + orphenadrine citrate |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Non-opioid analgesic (substance) |
Inferred relationship |
Some |
|
| Product containing chlormezanone and paracetamol (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Non-opioid analgesic (substance) |
Inferred relationship |
Some |
|
| Acetaminophen+diphenhydramine hydrochloride |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Non-opioid analgesic (substance) |
Inferred relationship |
Some |
|
| Product containing butalbital and caffeine and paracetamol (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Non-opioid analgesic (substance) |
Inferred relationship |
Some |
|
| Product containing oxycodone hydrochloride and paracetamol |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Non-opioid analgesic (substance) |
Inferred relationship |
Some |
|
| Product containing butalbital and paracetamol (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Non-opioid analgesic (substance) |
Inferred relationship |
Some |
|
| Isometheptene mucate+acetaminophen |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Non-opioid analgesic (substance) |
Inferred relationship |
Some |
|
| Product containing butalbital and caffeine and codeine phosphate and paracetamol |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Non-opioid analgesic (substance) |
Inferred relationship |
Some |
|
| Product containing methionine and paracetamol (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Non-opioid analgesic (substance) |
Inferred relationship |
Some |
|
| Acetaminophen + dichloralantipyrine + isometheptene mucate |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Non-opioid analgesic (substance) |
Inferred relationship |
Some |
|
| Acetaminophen + chloralantipyrine + isometheptene mucate |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Non-opioid analgesic (substance) |
Inferred relationship |
Some |
|
| Product containing paracetamol and propoxyphene napsylate |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Non-opioid analgesic (substance) |
Inferred relationship |
Some |
|
| Paracetamol 160 mg chewable tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Non-opioid analgesic (substance) |
Inferred relationship |
Some |
|
| Product containing paracetamol and promethazine hydrochloride |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Non-opioid analgesic (substance) |
Inferred relationship |
Some |
|
| Acetaminophen + chlorpheniramine maleate + phenylephrine hydrochloride |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Non-opioid analgesic (substance) |
Inferred relationship |
Some |
|
| Product containing metoclopramide and paracetamol (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Non-opioid analgesic (substance) |
Inferred relationship |
Some |
|
| Product containing domperidone maleate and paracetamol |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Non-opioid analgesic (substance) |
Inferred relationship |
Some |
|
| Product containing caffeine and dihydrocodeine tartrate and paracetamol |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Non-opioid analgesic (substance) |
Inferred relationship |
Some |
|
| Acetaminophen + codeine phosphate |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Non-opioid analgesic (substance) |
Inferred relationship |
Some |
|
| Codeine phosphate 15 mg and paracetamol 500 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Non-opioid analgesic (substance) |
Inferred relationship |
Some |
|
| Product containing precisely paracetamol 500 milligram/1 each conventional release effervescent oral tablet (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Non-opioid analgesic (substance) |
Inferred relationship |
Some |
|
| Product containing precisely paracetamol 500 milligram and pseudoephedrine hydrochloride 30 milligram/1 each conventional release oral tablet (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Non-opioid analgesic (substance) |
Inferred relationship |
Some |
|
| Product containing paracetamol and pseudoephedrine hydrochloride |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Non-opioid analgesic (substance) |
Inferred relationship |
Some |
|
| Acetaminophen 1g/sachet powder |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Non-opioid analgesic (substance) |
Inferred relationship |
Some |
|
| Paracetamol 250 mg orodispersible tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Non-opioid analgesic (substance) |
Inferred relationship |
Some |
|
| Product containing precisely caffeine 60 milligram and dihydrocodeine tartrate 32 milligram and paracetamol 712.8 milligram/1 each conventional release oral tablet (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Non-opioid analgesic (substance) |
Inferred relationship |
Some |
|
FHIR
© HL7.org
|
Server Home |
FHIR Server FHIR Server 3.7.22-SNAPSHOT
|
FHIR Version n/a
User: [n/a]